OBJECTIVE: Parental sleep quality may contribute to glycemic control in youth with type 1 diabetes. In this article we present sleep analysis from a multicenter, randomized trial of children ages 6–13 years with type 1 diabetes evaluating the Tandem Control-IQ (CIQ) hybrid closed-loop (HCL) system. RESEARCH DESIGN AND METHODS: Pittsburgh Sleep Quality Index (PSQI) scores were assessed at baseline to identify parents as “poor” sleepers (PSQI >5). Glycemic and psycho-behavioral outcomes before and after CIQ use were analyzed in poor sleepers (n = 49) and their children. RESULTS: Nocturnal time in range (P < 0.001) and time hyperglycemic (P < 0.001), Hypoglycemia Fear Survey for Parents score (P < 0.001), Problem Areas in Diabetes scale score (P < 0.001), PSQI score (P < 0.001), and Hypoglycemia Fear Survey for Children score (P = 0.025) significantly improved. Of poor sleepers, 27 became good sleepers (PSQI score <5). CONCLUSIONS: Use of CIQ in youth with type 1 diabetes ages 6–13 years significantly improved sleep and psychosocial measures in parent poor sleepers, coinciding with improvements in child nocturnal glycemia, highlighting the relationship between HCL systems and parent sleep quality.
Objective: To develop and evaluate a novel Web-based Simulation Tool (WST) that brings simulation technologies to people with Type 1 Diabetes (T1D), enabling unique patient-data interactions seamlessly on a daily basis. Methods: A pilot clinical trial was conducted to assess system usability. The study consisted of one week of observation (Phase 1) and four weeks of interaction with WST (Phase 2). Responses to Technology Acceptance (TA) and Diabetes Distress Scale (DDS) questionnaires were collected, and follow-up interviews were conducted after Phase 2. Results: Fifteen participants with T1D using Control-IQ technology (age: 36 $\pm$ 13 years, HbA1c: 6.5% $\pm$ 0.7%) completed all study procedures. Generated simulation models achieved a median Mean Absolute Relative Difference (MARD) of 6.8% [interquartile range, IQR: 5.1%, 9.1%]. A decrease in expected benefits (likely explained by issues with the third-party data collection system) and an increase in expected burdens were observed. On a 1-5 scale, ease of use, trust, and usefulness scores were 3 [3,4], 4 [3,4], and 4 [3,4], respectively. Time below 70 mg/dL decreased between Phases 1 and 2 (1.6% [0.7%,3.7%] vs 0.8% [0.5%,3.0%]). A reduction in mean emotional burden was also observed (2.5 $\pm$ 1.1 vs 2.1 $\pm$ 0.8). Conclusions: Results indicate that there was a learning curve to WST, but also that most participants trusted the system and found it useful in their diabetes care. Significance: Simulation technologies like WST could be used by educators and patients to facilitate diabetes self-management, leading to better diabetes literacy and reducing associated distress.
12 October 2023 in Diabetes Technology & Therapeutics
Individuals with type 1 diabetes of minoritized race-ethnicities and low-socioeconomic status (SES) do not access nor use automated insulin delivery (AID) technology at equal rates compared to their non-Hispanic White (NHW) and high SES counterparts. Using four AID trials (n=292), we ran linear mixed models to compare glycemic outcomes using race/ethnicity, education, and income. These trials overrepresented NHW (83%), high-income (91%), and highly educated (86%) populations. By education, participants with <bachelor's degree had worse baseline glycemic control than those with ≥bachelor's degree as per HbA1c: 7.83% vs. 7.25% (p<0.001), time-in-range: 50.1% vs. 61.2% (p180 mg/dL: 46.2% vs. 34.5% (p<0.001). These differences disappeared following AID use. By race/ethnicity and income groups, there were no differences in baseline glycemic control. While baseline glycemic control tended to be worse for underrepresented populations, AID glycemic efficacy was approximately equivalent. These results suggest improving accessibility to AID could equalize glycemic outcome disparities.